Tekmira Pharmaceuticals' (TKMR -1.1%) Ebola-stoked up move may be stalling. Shares are showing a bearish reversal in early trading. Prices have retreated 15% from the intraday high of $16.87 on a massive 14x surge in volume.
The two U.S. aid workers infected with the virus were treated with an experimental drug that was rushed to Africa. One of the workers improved dramatically one hour after dosing. The problem for Tekmira bulls is that the drug was supplied by privately-held Mapp Biopharmaceuticals. Some observers believe this may lessen the FDA's motivation to lift the clinical hold on the company's Phase 1 healthy volunteer trial.